Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182659 | 0.85 | MMP13 (0.49) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6167249 | 0.83 | MMP13 (0.56) | MMP13SLC22A8 | |
| SCHEMBL6168245 | 0.83 | MMP13 (0.45) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6178058 | 0.83 | MMP13 (0.49) | MMP13SLC22A8PSMB1PSMB2 | |
| SCHEMBL6175267 | 0.83 | TNF (0.50) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6179123 | 0.83 | MMP13 (0.43) | MMP13SLC22A8PSMB1PSMB2TNF | |
| SCHEMBL6180019 | 0.83 | MMP13 (0.51) | MMP13SLC22A8PSMB1PSMB2PSMB5 | |
| SCHEMBL6704440 | 0.81 | TNF (0.59) | MMP13SLC22A8TNF | |
| SCHEMBL6700403 | 0.81 | MMP13 (0.48) | MMP13SLC22A8TNF | |
| SCHEMBL6170469 | 0.81 | MMP13 (0.44) | MMP13SLC22A8TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | MMP13 2/4885SLC22A8 1532/4885PSMB1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.